Dr. Rafat Abonour, MD
Claim this profileIndiana University/Melvin and Bren Simon Cancer Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
7 reported clinical trials
11 drugs studied
Area of expertise
1Multiple Myeloma
Stage I
Stage II
Stage III
2Plasma Cell Neoplasm
Stage I
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Rafat Abonour, MD is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
GM T Cell Therapy Long-Term Follow-Up
for Cancer
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3
More about Rafat Abonour, MD
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rafat Abonour, MD has experience with
- Lenalidomide
- Dexamethasone
- Bortezomib
- Daratumumab And Hyaluronidase-fihj
- Daratumumab
- Daratumumab/rHuPH20
Breakdown of trials Rafat Abonour, MD has run
Multiple Myeloma
Plasma Cell Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rafat Abonour, MD specialize in?
Rafat Abonour, MD focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Stage I patients, or patients who are Stage II.
Is Rafat Abonour, MD currently recruiting for clinical trials?
Yes, Rafat Abonour, MD is currently recruiting for 4 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Rafat Abonour, MD has studied deeply?
Yes, Rafat Abonour, MD has studied treatments such as Lenalidomide, Dexamethasone, Bortezomib.
What is the best way to schedule an appointment with Rafat Abonour, MD?
Apply for one of the trials that Rafat Abonour, MD is conducting.
What is the office address of Rafat Abonour, MD?
The office of Rafat Abonour, MD is located at: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University/Melvin and Bren Simon Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.